Sahm ScreenerSaudi Stock Screenerفلتر الأسهم السعودية
Home / Jamjoom Pharmaceuticals Factory Co. / 2024 Annual Results

Jamjoom Pharmaceuticals Factory Co. 2024 Annual Results

Revenue
SAR 1.32B
Net Profit
SAR 357M
EPS
SAR 5.09
Operating Cash Flow
SAR 263M

Jamjoom Pharmaceuticals Factory Co. (4015) reported full year 2024 revenue of SAR 1.32B, up 19.8% from SAR 1.10B in 2023. Net profit came in at SAR 357M, up 21.9% year on year. Earnings per share were SAR 5.09. The company generated SAR 263M in operating cash flow. All figures sourced from CMA-mandated XBRL filings on the Saudi Exchange, processed by Sahm Screener.

Earnings Quality

Of every SAR 1.00 in reported net profit, SAR 0.74 arrived as operating cash flow — indicating Moderate quality earnings with a cash conversion ratio of 0.74.

Key Financial Metrics

Metric20242023
RevenueSAR 1.32BSAR 1.10B
Net ProfitSAR 357MSAR 292M
Net Margin27.0%26.6%
ROE23.9%20.8%
EPSSAR 5.09SAR 4.18
Total AssetsSAR 1.77BSAR 1.65B
Total EquitySAR 1.49BSAR 1.40B
Total LiabilitiesSAR 281MSAR 250M
Operating Cash FlowSAR 263MSAR 296M

Year on Year Comparison

Revenue increased by 19.8% compared to 2023. Net profit increased by 21.9%. Both revenue and profit grew — indicating expanding business.

View full company profile →
View all years:
2025202420232022202120202019

Financial data sourced from CMA-mandated XBRL filings published on the Saudi Exchange (Tadawul). Data processed and structured by Sahm Screener (sahmscreener.com). Updated nightly. Last updated: 2025-03-04.